In adolescents with ADHD and substance-use disorder (SUD), three open (n = 42 subjects) and five controlled (n = 557 subjects) studies were identified. Similarly, in adults with ADHD plus SUD, six open (n = 124 subjects) and seven controlled (n = 703 subjects) studies were identified. Studies included both stimulants and nonstimulants used in the treatment of ADHD.
review Wilens & Morrison ADHD is among the most prevalent neuro behavioral disorders presenting for treatment in children and adolescents [1] . Between 6 and 9% of youths and 4-5% of adults have ADHD worldwide [2, 3] . ADHD is associated with a per sistent course, impairment in multiple domains, and cooccurring learning and psychiatric problems (for a review see [4] ). Cigarette and substanceuse disorders (SUDs) remain among the most problematic cooccurring disorders with ADHD.
SUDs onset is usually in adolescence or early adulthood and affects up to 30% of US adults [1, 5] with approximately 9% of adolescents mani festing a druguse disorder and 6% an alcohol use disorder [1] . The study of comorbidity between SUD and ADHD is germane to both research and clinical practice in develop mental pediatrics, psychology and psychiatry, with implications for diagnosis, prognosis, treatment and healthcare delivery.
There appears to be a bidirectional relation ship between ADHD and SUD. From a quarter to a half of adolescents and adults with SUD have ADHD (for a review see [6, 7] ). For instance, in samples of cannabisabusing youths, ADHD occurs in 40-50% of both girls and boys. In adult groups with SUD, a higher risk for ADHD (~20-25%), as well as earlier onset and more severe SUD, has been linked with ADHD [8, 9] . It is also thought that ADHD remains under identified in addiction treatment centers. For example, in one study, while 3% of individuals in a residential treatment center were noted in the records as having ADHD, systematic assess ment using a standardized screener identified a rate of ADHD of 44% [10] .
ADHD and accompanying comorbidity is also a risk for SUD as demonstrated in a recent metaanalysis [11] . Charach et al. reported on 13 studies of ADHD youths growing up and found that a significant increase in SUD was associated with ADHD [11] . Prospective data also shows that cooccurring conduct or bipolar disorders beget the highest risk for SUD [12] [13] [14] [15] [16] . Interestingly, the authors recently examined other internal characteristics in ADHD that may predict later SUD and found that fam ily history of SUD, cognitive impairment, executive dysfunction, socialization or fam ily environ ment did not predict SUD in the 10year followup of prepubescent children with ADHD [16, 17] .
The stimulants remain among firstline agents for the treatment of ADHD across the lifespan [18] . As controlled substances, the stimulant abuse liability and potential kindling of specific types of later abuse (i.e., cocaine) secondary to earlier stimulant exposure in ADHD children have been raised [19] . It appears that stimulant treatment does not increase the risk for SUD. Data seem to suggest a reduction in the risk and delay of onset of SUD through adolescence [20] in stimulanttreated youths with ADHD that appears to be lost in adulthood [21] . It is possible that the protective effect in adults may be lost, in part, owing to the fact that findings in adoles cents do not span through the full age of risk of SUD. Also, most adolescents have stopped their ADHD treatment during later adolescence and young adulthood. This suggests the potential loss of the protective effect of stimulants in later years. While the mechanism of ADHD result ing in SUD remains unclear, family genetics, self medication, exposure to SUD and common biological pathways remain the most likely candidates [7, 16, 22, 23] .
While aggregate data exists on the preven tion of SUD in context to ADHD treatment [24] , a number of questions related to the impact of ADHD treatment on individuals affected with both ADHD and SUD remain. For instance, do specific psychosocial treatments such as cognitive behavioral therapy (CBT) or dynamic psychotherapies exist to treat concomi tant ADHD and SUD? Likewise, does ADHD pharmacotherapy in context with SUD improve the subject's ADHD or does it reduce or exac erbate SUD? Previous clinical guidelines, while helpful, were completed prior to the benefit of a number of recent open and controlled trials [25] [26] [27] . To this end, to evaluate the treatment of effects, worsening of SUD, misuse or diversion of stimulants are reported in the included studies. Treating ADHD pharmacologically in individuals with ADHD plus SUD only has a modest impact on ADHD and SUD that is not observed in controlled trials. Limited data in adults with ADHD and brief abstinence of their SUD showed improvements in both ADHD and SUD with treatment. Further studies of cognitive behavioral therapy, sequencing of therapies and longer term treatment outcomes for groups with ADHD and active SUD are necessary.
adolescents and adults with ADHD and SUD the literature are reviewed.
Methods
A search of the literature included journal arti cles using keywords including 'SUD derivatives', 'antidepressants', 'nonstimulants', 'stimulants', 'pharmacotherapy' and 'ADHD'. Prospective treatment studies examining the effect of psy chosocial and/or pharmacological treatment in adults or adolescents with ADHD and SUD were included, and our search was supplemented with data from a variety of peerreviewed scien tific presentations at national and international scientific conventions and meetings.
Included were articles with adolescents or adults who met the Diagnostic and Statistical Manual of Mental Disorders IIIRevised or IV criteria for current ADHD and had an active SUD. Studies had to be prospective and treat participants psychosocially or pharmacologically for ADHD. The sample size of each study had to be at least ten. Excluded were articles that lacked current diagnoses of ADHD and SUD, did not provide quantitative outcome information, were retrospective or were case reports/studies.
Results

Cognitive behavioral therapy
Despite the frequent comorbidity of ADHD and SUD, there is a dearth of literature exam ining psychotherapy exclusively for individuals with both disorders. However, recent studies have demonstrated efficacy of CBT for ADHD and related problems in adults with ADHD using both individual [28] and group [29] thera pies. While specific trials of psychotherapies in ADHD and SUD are lacking, data from recently reported studies shed some light on the poten tial usefulness of psychotherapies. A recently reported, wellconducted multisite controlled study of adolescents with mixed SUD and ADHD found that both groups improved in both ADHD and SUD independent of the study medication (osmoticrelease oral system [OROS] methylphenidate [MPH] ), leading the authors to posit that the improvement may have been related to the CBT provided to all adolescents in the study [30] . Similar findings were reported in a singlesite controlled trial of atomoxetine in adolescents with ADHD and SUD [31] . Clearly, more work examining the role of modified CBT addressing both ADHD and SUD in adolescents and adults with ADHD and SUD is necessary.
Effective medications for ADHD include the stimulants, aagonists, noradrenergic agents and catecholaminergic antidepressants [18] .
Medications Stimulants
In general, while open studies are more encour aging, results from controlled trials with stim ulants and/or bupropion suggest that ADHD pharmaco therapy used in adolescent and adult groups with ADHD plus mixed SUD has mea ger effects on ADHD and substance use or crav ings (Tables 1 & 2) . In an early 13week random ized controlled study, Schubiner and colleagues reported that MPH was linked to small but significant reductions in symptoms of ADHD without changes in cocaine use or cravings [32] . Levin et al. in two published studies of MPH and/or bupropion in adults with cocaine addic tion (± opioid replacement with methadone) found only small to no improvements in ADHD and SUD outcomes [33, 34] . In a more recent pilot study of 24 adults with amphetamine abuse and ADHD, Konstenius et al. conducted a 12week, placebocontrolled trial of OROS MPH (72 mg). No significant differences in outcome for either ADHD or SUD were found [35] .
A related multisite controlled study of stimu lants in adult smokers with ADHD indicated a similar outcome [36] . In this 11week study, 255 adults with ADHD who were treated with the nicotine patch to examine the effects on ciga rette cessation and ADHD were also dosed to 72 mg/day of OROS MPH/placebo. The results of this trial showed improved ADHD but no effects on rates of cigarette cessation [36] . Of inter est, despite recent concerns of stimulants poten tially increasing cigarette smoking in ADHD [37] , there was no increased cigarette smoking in the medicated group and side effects in these adults were similar to those noted in previous stimulant trials. In a 16week placebocontrolled multisite study, 300 adolescents with mixed SUD (not including opioid abuse) received 72 mg/day OROS MPH/placebo along with weekly indi vidual CBT resulting in no significant improve ment in ADHD (investigator/parent) or SUD (adolescent selfreport) between treatment groups. Side effects were reminiscent of adoles cent studies and the medication was reported to be of lowabuse liability. As in the study by Riggs, no evidence exists that treating ADHD with stimulants through an active SUD worsens the SUD [38] -consistent with longstanding work review Wilens & Morrison One subject was using benzodiazepine 24% of subjects dropped out of the study [69] Levin et al. review Wilens & Morrison of Grabowski and colleagues who used stimu lants ('agonist therapy') to block cocaine and amphetamine abuse [39] .
Nonstimulants
Owing to the broad spectrum of activity in ADHD and a lack of abuse liability [40] , atom oxetine has been examined for its usefulness in ADHD plus SUD [41] . In this 12week multi site study in recently abstinent adult alcoholics, atom oxetine (compared with placebo) was effec tive in treating ADHD and in reducing recur rent episodes of heavy drinking, but not relapse to heavy drinking [41] . Similarly, in a small 10week, openlabel study, atomoxetine treated ADHD symptoms and reduced the intensity, fre quency and length of cravings in recently absti nent adults with SUD and comorbid ADHD [42] . Atomoxetine administration in relatively heavy compared with light or nondrinkers was associated with more side effects; however, no serious adverse events nor evidence of impaired liver functioning emerged in the heavy drinkers in these relatively shortterm trials [43] . Although these data in abstinent alcoholics appear promis ing, results should be tempered against a recent study in currently using adolescents with SUD. In this study, 70 adolescents with ADHD and at least one active nonnicotine SUD received motivational interviewing/CBT in addition to atomoxetine or placebo for 12 weeks [31] . No differences emerged in the use of substances or ADHD scores between treatment groups during this study. The aforementioned findings together with an older metaanalysis of ten studies suggest that medications used in ADHD populations with comorbid SUD only have a minor effect on ADHD and have little effect on substance use, cigarette use or cravings [44] . In two recent stud ies where there was some abstinence from sub stances prior to treating ADHD, improvement in both the ADHD and SUD were reported [41, 42] . It may be that treatment of comorbid ADHD and SUD improves ADHD symptoms as has been reported for other conditions (e.g., unstable mood) [45, 46] or alternatively, that by nature of the brief abstinence, these patients are different than groups who have not been able to maintain any sobriety. Future studies examin ing sequential treatments compared with parallel treatments of ADHD and SUD are necessary to better understand the extent and mechanism of change. 
Misuse & diversion
There is continued interest in diversion and misuse of stimulants prescribed for ADHD (for a review see [47] ). While the vast majority of adolescents and adults treated for ADHD appropriately use their medication [22, [47] [48] [49] , a number have also reported being pressured into giving away or selling their medication [50] [48, 49] . This practice is more common in competitive colleges where the stimulants are more often misused for their procognitive effects than euphoria [49] . A minority of college students 'scam' local practitioners for stimulants whereas the bulk of college students who misuse stimu lants obtain them from friends [51] . Stimulant misuse is often in context with substance abuse [52] and delinquency [22, 47] . Specific stimulant preparations may impact misuse and diversion [7, 18] with lower likeability and less misuse of extendedrelease stimulants, compared with immediaterelease stimulants reported in preclinical [53] [54] [55] , clinical [22, 56] and epidemiological reports [57] . While misuse and diversion are clearly to be monitored in SUD, interestingly, studies of treating SUD in ADHD seem to suggest the relative safety of stimu lants. For instance, Winhusen and colleagues [58] reexamined two large multisite studies of OROS MPH in adolescents with mixed SUD and ADHD [30] and adults with cigarette smok ing and ADHD [36] to evaluate its overall 'risk' in these populations. These authors found that compared with placebo, subjects did not signifi cantly misuse OROS MPH or experience differ ences in cravings for their medication or other substances. There was a greater euphorgenic effect of OROS MPH compared with placebo that was not linked to the severity of SUD. The authors concluded that the stimulant could be used safely in subjects with mixed SUD.
Conclusion & future perspective
Adolescents and adults with ADHD and SUD are increasingly presenting for diagnosis and treatment in both clinical practices manag ing ADHD and in SUDoriented treatment centers. A growing literature highlights the importance of recognizing both disorders [59] . In specifically accessing the treatment needs of these patients, adolescents and adults with ADHD and SUD require multimodal interven tion incorporating addiction and mental health treatment. While not directly tested, a host of studies strongly suggest that CBT may be effec tive in both ADHD and SUD [28] [29] [30] [31] . The data seem to suggest that treating ADHD individu als with active SUD pharmacologically is not particularly useful to treat either condition, and clinicians should pay particular attention to these findings over the next decade. Based on older guidelines, if possible, substance use should be stabilized prior to initiating phar macotherapy [25] . Choice of nonstimulants or extendedrelease stimulants should be con sidered to treat those with recent addictions or those at high risk to misuse or divert their medications. Given the high prevalence and major morbidity of ADHD and SUD, studies of sequential and parallel multimodal treat ment strategies addressing SUD and ADHD are necessary. This recent meta-analyses of 13 studies suggest childhood ADHD is associated with alcohol-and drug-use disorders in adulthood, and with nicotine use by middle adolescence.
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